Increased lipid peroxidation in sera of ALS patients: A potential biomarker of disease burden

Neurology

Volumn 62, Issue 10, 2004, Pages 1758-1765

  Simpson, E P ^a   Henry, Y K ^a   Henkel, J S ^a   Smith, R G ^a,b   Appel, S H ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Department of Neurology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; BETA CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 2442701519     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.62.10.1758     Document Type: Article

References (57)

1. Pedersen WA, Fu W, Keller JN, et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 1998;44:819-824.
2. Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-2074.
3. Oteiza PI, Uchitel OD, Carrasquedo F, Dubrovski AL, Roma JC, Fraga CG. Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res 1997;22:535-539.
4. Troost D, Van den Oord JJ, Vianney de Jong JM. Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral slerosis. Neuropathol Appl Neurobiol 1990;16:401-410.
5. Ono S, Hu J, Shimizu N, Imai T, Nakagawa H. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J Neurol Sci 2001;187:27-34.
6. Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 1998;154:194-199.
7. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128.
8. Subramanianm R, Roediger F, Jordan B, et al. The lipid peroxidation product 4-hydroxy-2-transnonenal alters the conformation of cortical synaptosomal membrane proteins. J Neurochem 1997;69:1161-1169.
9. Malecki A, Garrido R, Mattson MP, Hennig B, Toboreck M. 4-Hydroxynonenal induces oxidative stress and death of cultured spinal motor neurons. J Neurochem 2000;74:2278-2287.
10. Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 2002;52:448-457.
11. Pedersen WA, Cashman NR, Mattson MP. The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Exp Neurol 1999;155:1-10.
12. Lovell MA, Markesberry WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 1997;68:255-264.
13. Neely MD, Sidell KR, Graham DG, Montine TJ. The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J Neurochem 1999;72:2323-2333.
14. Picklo MJ, Amarnath V, McIntyre JO, Graham DG, Montine TJ. 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J Neurochem 1999;72:617-624.
15. Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 1998;44:696-699.
16. Farooqui AA, Yi Ong W, Lu XR, Halliwell B, Horrocks LA. Neurochemical consequences of kainate-induced toxicity in brain: involvement of arachidonic acid release and prevention of toxicity by phospholipase A(2) inhibitors. Brain Res Brain Res Rev 2001;38:61-78.
17. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acts. 1998;1366:211-223.
18. Jellinger KA. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 1999;14:115-140.
19. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 2001;21:8447-8455.
20. Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann NY Acad Sci 2002;962:318-331.
21. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992;140:691-707.
22. Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 1993;50:30-36.
23. Panzara MA, Gussoni E, Begovich AB, et al. T cell receptor BV gene rearrangements in the spinal cords and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiol Dis 1999;6:392-405.
24. Hoff HF, O'Neil J, Chisolm GM III, et al. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis 1989;9:538-549.
25. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-333.
26. Fox RI, Kang HI. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993;2(suppl 1):S9-S12.
27. Muller T, Kuhn W, Kruger R, Przuntek H. Selegiline as immunostimulant - a novel mechanism of action? J Neural Transm [Suppl] 1998;52:321-328.
28. Kantengwa S, Jornot L, Devenoges C, Nicod LP. Superoxide anions induce the maturation of human dendritic cells. Am J Respir Crit Care Med 2003;167:431-437.
29. Xiang L, Klintman D, Thorlacius H. Allopurinol inhibits CXC chemokine expression and leukocyte adhesion in endotoxemic liver injury. Inflamm Res 2003;52:353-358.
30. Holley AE, Cheeseman KH. Measuring free radical reactions in vivo. Br Med Bull 1993;49:494-505.
31. Rodenburg RJ, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Peripheral blood monocytes of rheumatoid arthritis patients do not express elevated TNF alpha, IL-1beta, and IL-8 mRNA levels. A comparison of monocyte isolation procedures. J Immunol Methods 1998;221:169-175.
32. Beal MF, Ferrante RJ, Browne SE, Mattews RT, Kowall NW, Brown RH Jr. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997;42:644-654.
33. Bogdanov M, Brown RH, Matson W, et al. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 2000;29:652-658.
34. Selley ML, Close DR, Stern SE. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 2002;23:383-388.
35. Selley ML. (E)4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med 1998;25:169-174.
36. Abe T, Isobe C, Murata T, Sato C, Tohgi H. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci Lett 2003;336:105-108.
37. Abe T, Tohgi H, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res 2002;70:447-450.
38. Wiedemann FR, Winkler K, Kuznetsov AV, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 1998;156:65-72.
39. Swerdlow RH, Parks JK, Cassarino DS, et al. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol 1998;153:135-142.
40. Curti D, Malaspina A, Facchetti G, et al. Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology 1996;47:1060-1064.
41. Allen NJ, Attwell D. A chemokine-glutamate connection. Nat Neurosci 2001;4:676-678.
42. Lampson LA, Kushner PD, Sobel RA. Major histocompatibility complex antigen expression in the affected tissues in amyotrophic lateral sclerosis. Ann Neurol 1990;28:365-372.
43. Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 1990;47:1210-1216.
44. Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 2001;193:713-726.
45. Glabinski AR, Balasingam V, Tani M, et al. Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol 1996;156:4363-4368.
46. McTigue DM, Tani M, Krivacic K, et al. Selective chemokine mRNA accumulation in the rat spinal cord after contusion injury. J Neurosci Res 1998;53:368-376.
47. Wilms H, Sievers J, Dengler R, Bufler J, Deuschl G, Lucius R. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol 2003;144:139-142.
48. Henkel JS, Engelhardt JI, Siklos L, et al. Presence of dendritic cells, increased chemokine MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis in spinal cord tissue. Ann Neurol 2004;55:221-235.
49. Woo Lee Y, Joo Park H, Hennig B, Toborek M. Linoleic acid induces MCP-1 gene expression in human microvascular endothelial cells through an oxidative mechanism. J Nutr Biochem 2001;12:648-654.
50. Curzio M, Esterbauer H, Poli G, et al. Possible role of aldehydic lipid peroxidation products as chemoattractants. Int J Tissue React 1987;9:295-306.
51. Rutault K, Alderman C, Chain BM, Katz DR. Reactive oxygen species activate human peripheral blood dendritic cells. Free Radic Biol Med 1999;26:232-238.
52. Aukrust P, Berge RK, Ueland T, et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001;37:485-491.
53. Chiarelli F, Cipollone F, Mohn A, et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 2002;25:1829-1834.
54. Kharbanda KK, Todero SL, Shubert KA, Sorrell MF, Tuma DJ. Malondialdehyde-acetaldehyde-protein adducts increase secretion chemokines by rat hepatic stellate cells. Alcohol 2001;25:123-128.
55. Nitti M, Domenicotti C, d'Abramo C et al. Activation of PKC-beta isoforms mediates HNE-induced MCP-1 release by macrophages. Biochem Biophys Res Commun 2002;294:547-552.
56. Chiarpotto E, Domenicotti C, Paola D, et al. Regulation of rat hepatocyte protein kinase C beta isoenzymes by the lipid peroxidation product 4-hydroxy-2,3-nonenal: a signaling pathway to modulate vesical transport of glycoproteins. Hepatology 1999;29:1565-1572.
57. Lee JS, Kahlon SS, Culbreth R, Cooper AD Jr. Modulation of monocyte chemokine production and nuclear factor kappa B activity by oxidants. J Interferon Cytokine Res 1999;19:761-767.